Stockscreener 앱 받기
0.9659
10.07%
0.0884
시간 외 거래:
.97
0.0041
+0.42%
전일 마감가:
$0.8775
열려 있는:
$0.8886
하루 거래량:
167.45K
Relative Volume:
0.02
시가총액:
$6.37M
수익:
$3,000
순이익/손실:
$-5.76M
주가수익비율:
-0.5229
EPS:
-1.8471
순현금흐름:
$-5.59M
1주 성능:
+0.55%
1개월 성능:
-10.56%
6개월 성능:
-48.62%
1년 성능:
-72.48%
1일 변동 폭
$0.8743
$0.9659
1주일 범위
$0.8213
$0.9728
52주 변동 폭
$0.62
$6.25
Creative Medical Technology Holdings Inc Stock (CELZ) Company Profile
명칭
Creative Medical Technology Holdings Inc
전화
480-399-2822
주소
211 E. OSBORN RD., PHOENIX
Compare CELZ vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CELZ
Creative Medical Technology Holdings Inc
|
0.9659 | 6.33M | 3,000 | -5.76M | -5.59M | -1.8471 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Creative Medical Technology Holdings Inc 주식(CELZ)의 최신 뉴스
EPS Creative Health Tech’s Controlling Shareholder to Sell 22% Stake While Retaining Control - TipRanks
These Three Stocks Fell More Than 10% Today To Hit 52-Week Lows -- What's Driving The Investor Skepticism? - Stocktwits
Creative Medical Technology Increases Authorized Shares to 100 Million - minichart.com.sg
Creative Medical Expands Authorized Shares and Warrant Exercise - TipRanks
Creative Medical Technology Holdings Inc. (CELZ) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
CELZ Holds Steady at $1.14 as Creative Medical Technology ConsolidatesChaikin Flow - dars.gov.et
Creative Medical Technology Holdings Inc. (CELZ) Peer Comparison – Compare with Others - Value Research
Creative Medical Technology Holdings Inc. (CELZ) Key Financial Ratios – Valuation, Profitability & More - Value Research
Creative Medical completes Olastrocel trial enrollment as it sets sights on FDA Phase 3 path - Indian Pharma Post
Rest-Of-Europe Exosome Research Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
CELZ Looks 171.4% Overvalued on GF Value™ - GuruFocus
CELZ Looks 142.9% Overvalued on GF Value™ - GuruFocus
Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning - The Manila Times
Creative Medical completes enrollment in chronic back pain trial - Investing.com
Creative Medical Technology Holdings Completes Enrollment And Treatment In FDA-Cleared ADAPT Clinical Trial Evaluating CELZ-201 / Olastrocel - marketscreener.com
Creative Medical finishes treating back-pain patients who use opioids - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Creative (CELZ) EPS and Revenue Review: The EPS Result Is Below Expectation on the Day; Market Follow-Through: The Share Price Sheds 1.82% on the DayGuidance Accuracy Score - vinanet.vn
CELZ Q2 2026 Earnings: Wider Loss of -$0.41 per Share Misses Estimates; Stock Falls 1.6%EPS Consistency Score - vinanet.vn
CELZ Q2 2026 Earnings: EPS Miss of -$0.41 Reflects Pre-Revenue Pipeline InvestmentCFO Commentary Report - vinanet.vn
Why Avalon Holdings Shares Are Trading Higher By More Than 10%; Here Are 20 Stocks Moving Premarket - Sahm
CELZ Q2 2026 Earnings: EPS Misses by 3.07% as Pre-Revenue Losses Persist; Stock Climbs 8.75%Cash Flow Report - vinanet.vn
Creative Medical Technology Holdings Inc (CELZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CELZ Jumps As New Diabetes Patent Fuels Volatile Rally - StocksToTrade
Creative Medical Technology | DEF 14A: Definitive information statements - Moomoo
Creative Medical net loss widens 22.5% to $1.51 million in Q2 2026 - Bitget
Creative Medical Technology Holdings, Inc. (CELZ) stock price, news, quote and history - Yahoo Finance Singapore
Creative Medical Technology Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. 2026: Revenue $0 Net income ($1.51M), EPS ($0.41) — 10-Q Summary - TradingView
Creative Medical Technology (NASDAQ: CELZ) Q2 loss, cash rises to $8.7M - Stock Titan
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Top Microcaps CELZ, PRSO, HCWC, TOON: Shorted Stocks to Watch in August 2026 - FinancialContent
Which stocks have an unusual volume on Friday? - ChartMill
Creative Medical Technology Holdings Inc (CELZ) Stock News Today - TradingKey
$Creative Medical Technology (CELZ.US)$ 小赚 - Moomoo
$Creative Medical Technology (CELZ.US)$ sky is so clear and the sun is out 🌄 - Moomoo
CELZ Stock Jumps As New Diabetes Patent Fuels Momentum - stockstotrade.com
$Creative Medical Technology (CELZ.US)$ 🫣 - Moomoo
$Creative Medical Technology (CELZ.US)$ double dipped😋 - Moomoo
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Creative Medical Technology Stock Surges After Key Patent Win - Benzinga
Thursday's session: most active stocks - ChartMill
Medical Stocks To ConsiderAugust 6th - MarketBeat
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Creative Medical receives patent allowance for diabetes exosome tech By Investing.com - Investing.com South Africa
Creative Medical Technology Holdings Shares Surge as Traders Appear to Latch Onto Earlier Pipeline Updates and a Tiny-float Setup - Moomoo
Creative Medical receives patent allowance for diabetes exosome tech - Investing.com
Creative Medical Receives U.S. Patent Allowance for Exosome-Based Type 1 Diabetes Immunotherapy - Yahoo Finance
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms - marketscreener.com
Exosome application gets U.S. allowance to target Type 1 diabetes autoimmunity - Stock Titan
Creative Medical Technology Holdings Inc (CELZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.88%
자본화:
|
볼륨(24시간):